Boryung Signs 383.6 Billion Won Taxotere Export Deal With China, Its First Major Result Since Acquiring Sanofi Rights

Boryung has signed a 383.6 billion won export supply agreement for the oncology drug Taxotere with Chinese pharmaceutical company Yifan Pharmaceutical. The deal, the largest finished-drug export contract in Boryung’s history, leverages a global brand the company acquired from France’s Sanofi last year and is being viewed as a new overseas expansion model for South Korean pharmaceutical companies.

From acquiring Sanofi rights to a major export agreement

Boryung disclosed on the 22nd that it had signed an export supply agreement with China’s Yifan Pharmaceutical for Taxotere, a breast cancer treatment. The contract is valued at 383,651.8 million won, equivalent to $277.14 million. That represents 37.71% of Boryung’s 2025 consolidated revenue of 1,017.4 billion won.

Taxotere is a global original cytotoxic oncology drug widely used to treat breast, prostate and lung cancers. In September last year, Boryung acquired Taxotere distribution and business rights in 19 countries, including South Korea, China, Germany and Spain, from Sanofi for $205 million. The company completed the acquisition in June this year. The Chinese export agreement is the first major result since the rights acquisition.

The agreement runs from Sept. 21, 2026, through Sept. 20, 2033. However, because the seven-year term is calculated from the date the transfer of the Chinese marketing authorization is completed, the end date may change depending on when that process is completed. Yifan Pharmaceutical, the counterparty, is listed on the Shenzhen Stock Exchange and had consolidated revenue of approximately 1,060 billion won in 2025. It has a sales network in more than 50 countries worldwide.

Minimum purchase obligation ensures stable revenue structure

A notable feature of the agreement is the inclusion of a mechanism designed to ensure stable revenue. Yifan Pharmaceutical is required to purchase at least 90% of the confirmed volume for each contract year. If it falls short, it must compensate Boryung in cash for the entire shortfall at the contracted supply price. Accordingly, 90% of the contract value will be paid to Boryung either through purchases or cash compensation.

According to a report released in September this year by global market research firm The Business Research Company, the taxane oncology drug market, which includes Taxotere, is projected to grow at an average annual rate of 4.7%, from $6.47 billion in 2025 to $8.11 billion in 2030. Based on data from China’s National Cancer Center, the number of new cancer cases in China reached approximately 5.15 million in 2025. Frost & Sullivan analyzed that China’s oncology drug market is expected to grow rapidly from $39 billion in 2025 to more than $129.3 billion in 2034. China is by far the largest consumer market among the 19 countries covered by the Taxotere business rights.

“This agreement is significant because we did not simply acquire the global Taxotere brand; we will directly manage the product life cycle and have secured a seven-year foundation of long-term demand and supply in China, a key market,” said Sung-jin Kim, executive vice president and chief strategy officer of Boryung. “Based on this, we will work toward achieving our goal of 300 billion won in overseas revenue by 2030.”

Global expansion potential opened by legacy-brand acquisition strategy

The agreement also offers implications for how South Korean biopharmaceutical companies expand overseas. Whereas companies have traditionally relied heavily on out-licensing drug candidates, Boryung has chosen to acquire patent-expired original medicines and directly control their global distribution networks. Although cancer treatment is evolving toward targeted and immuno-oncology therapies, cytotoxic oncology drugs such as Taxotere remain an essential foundation of cancer treatment and are listed on the World Health Organization’s Model List of Essential Medicines, supporting stable global demand.

Boryung plans to fully transfer Taxotere production to dedicated sterile cytotoxic oncology facilities at its Yesan Campus in South Chungcheong province after completing technology transfer and regulatory variation procedures. Once in-house production is complete, the company expects to maximize cost savings and significantly increase its operating margin.

The large, long-term contract in China is expected to pave the way for additional exclusive supply agreements with major local distributors in European markets, including Germany and Spain, where Boryung holds the rights, as well as in other Asian countries. As shortages of generic oncology drugs have become increasingly frequent in major countries, including the United States, attention is focused on whether Boryung’s Taxotere, combining the credibility of an original brand with South Korea’s stable manufacturing capabilities, can emerge as an attractive alternative amid global supply chain disruptions.